Pharmacokinetic drug–drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol

Publisher： John Wiley & Sons Inc

E-ISSN： 2160-7648|4|6|407-417

ISSN： 2160-763X

Source： Clinical Pharmacology In Drug Development, Vol.4, Iss.6, 2015-11, pp. : 407-417

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lack of Pharmacokinetic Drug-Drug Interaction between Orlistat and Cerivastatin

By Mück W.   Adelmann H-G.   Ruf T.   Unger S.   Voith B.  

Clinical Drug Investigation, Vol. 19, Iss. 1, 2000-01 ,pp. : 71-73

Adis International

Access to resources Recommend Favorite

Drug-Drug Interaction Prediction Assessment

By Zhou Jihao  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 4, 2009-07 ,pp. : 641-657

Taylor & Francis Ltd

Access to resources Recommend Favorite

What is the true risk of a pharmacokinetic drug–drug interaction?

By Fuhr Uwe  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 10, 2007-10 ,pp. : 897-899

Springer Publishing Company

Access to resources Recommend Favorite

Angiotensin receptor blockers and drug–drug interactions

By Sica Domenic A  

Expert Opinion on Drug Safety, Vol. 4, Iss. 1, 2005-01 ,pp. : 139-140

Informa Healthcare

Access to resources Recommend Favorite

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers

By  

Clinical Pharmacology In Drug Development, Vol. 7, Iss. 2, 2018-02 ,pp. : 143-150

John Wiley & Sons Inc

Access to resources Recommend Favorite